Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the effect of veliparib in ovarian cancer
patients with known BRCA 1/2 mutations who do no longer respond to conventional chemotherapy.